Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.
Jeffrey Wolf, MD, of the University of California San Francisco, discussed the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma in an interview with CancerNetwork.
This year, I’m seeing the results with T-cell engagers (TCE) and believing that, although we’re probably not curing anyone, we’re getting at least as good results as we are with CAR Ts, so maybe we’ve leapfrogged with TCEs beyond CAR Ts. But I’m looking forward, in the next few years, to next-generation CAR Ts, maybe dual CARs that will attack more than 1 target. And that will probably leapfrog the TCEs. So, I think ultimately, we’re going to be looking at either drugs or cells that are going to give us 3-4 years of control or cure. And I really think that we’re probably 5 years away from truly curing some of our patients.